Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.

Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, Young RC, Alberts DS, McGuire WP, Markman M, Bell J, Ozols RF, Armstrong DK, Aghajanian C, Bookman MA, Mannel RS.

Gynecol Oncol. 2019 Aug;154(2):420-425. doi: 10.1016/j.ygyno.2019.05.013. Epub 2019 Jun 19.

PMID:
31229298
2.
3.

The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.

Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, Stany MP, Rose GS, Markman M, Ozols RF, Armstrong DK, Maxwell GL.

Gynecol Oncol. 2011 Sep;122(3):521-6. doi: 10.1016/j.ygyno.2011.04.041. Epub 2011 Jun 17.

4.

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.

Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK.

Cancer. 2009 Apr 1;115(7):1395-403. doi: 10.1002/cncr.24152. Review.

5.

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.

Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK.

Cancer. 2009 Mar 1;115(5):1028-35. doi: 10.1002/cncr.24084.

6.

Ovarian cancer. Clinical practice guidelines in oncology.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Grigsby PW, Havrilesky LJ, Johnston C, Lancaster JM, Lele S, Matulonis U, O'Malley D, Ozols RF, Remmenga SW, Sabbatini P, Schink J, Teng N; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2008 Sep;6(8):766-94. No abstract available.

PMID:
18926089
7.

Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer.

Ozols RF.

Adv Exp Med Biol. 2008;622:131-43. doi: 10.1007/978-0-387-68969-2_11. Review. No abstract available.

PMID:
18546624
8.

Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W Jr, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS; American Society of Clinical Oncology.

J Clin Oncol. 2008 Jan 10;26(2):313-25. Epub 2007 Dec 17. Erratum in: J Clin Oncol. 2008 Mar 10;26(8):1394.

PMID:
18086794
9.

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP; Gynecologic Oncology Group Study.

J Clin Oncol. 2007 Aug 20;25(24):3621-7.

PMID:
17704411
10.

Ovarian cancer: is dose intensity dead?

Ozols RF.

J Clin Oncol. 2007 Sep 20;25(27):4157-8. Epub 2007 Aug 13. No abstract available.

PMID:
17698802
11.

Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS.

Gynecol Oncol. 2007 Nov;107(2):260-5. Epub 2007 Aug 6.

12.

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.

Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR.

Clin Cancer Res. 2007 Jul 15;13(14):4261-70.

13.

The management of recurrent ovarian cancer.

Bukowski RM, Ozols RF, Markman M.

Semin Oncol. 2007 Apr;34(2 Suppl 2):S1-15. Review. No abstract available.

PMID:
17512352
14.

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ; American Society of Clinical Oncology.

J Clin Oncol. 2007 Jan 1;25(1):146-62. Epub 2006 Dec 8.

PMID:
17158528
15.

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.

Alberts DS, Markman M, Muggia F, Ozols RF, Eldermire E, Bookman MA, Chen T, Curtin J, Hess LM, Liebes L, Young RC, Trimble E.

Gynecol Oncol. 2006 Dec;103(3):783-92. Epub 2006 Oct 27.

16.

Ovarian cancer. Clinical practice guidelines in oncology.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Johnston C, Lancaster JM, Lele S, Matulonis U, Ozols RF, Remmenga SW, Sabbatini P, Soper J, Teng N; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Oct;4(9):912-39. No abstract available.

PMID:
17020669
17.

Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.

Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC.

Gynecol Oncol. 2006 Oct;103(1):1-6. Epub 2006 Aug 10. No abstract available.

PMID:
16904166
18.

Challenges for chemotherapy in ovarian cancer.

Ozols RF.

Ann Oncol. 2006 May;17 Suppl 5:v181-7. Review.

PMID:
16807453
19.

Systemic therapy for ovarian cancer: current status and new treatments.

Ozols RF.

Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11. Review.

PMID:
16716797
20.

Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations.

Cai KQ, Klein-Szanto A, Karthik D, Edelson M, Daly MB, Ozols RF, Lynch HT, Godwin AK, Xu XX.

Gynecol Oncol. 2006 Nov;103(2):719-28. Epub 2006 May 12.

PMID:
16698071
21.

Intraperitoneal chemotherapy for ovarian cancer.

Ozols RF, Bookman MA, Young RC.

N Engl J Med. 2006 Apr 13;354(15):1641-3; author reply 1641-3. No abstract available.

PMID:
16611959
22.

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ; American Society of Clinical Oncology.

J Clin Oncol. 2006 Jan 1;24(1):190-205. Epub 2005 Dec 2.

PMID:
16326753
23.

Clinical trials in ovarian carcinoma: study methodology.

Vermorken JB, Parmar MK, Brady MF, Eisenhauer EA, Hogberg T, Ozols RF, Rochon J, Rustin GJ, Sagae S, Verheijen RH; Gynecologic Cancer Intergroup; EORTC; MRC/NCRI; GOG; NCIC-CTG; NSGO; AGO-OVAR; JGOG.

Ann Oncol. 2005;16 Suppl 8:viii20-viii29. No abstract available.

PMID:
16239233
24.

Gemcitabine and carboplatin in second-line ovarian cancer.

Ozols RF.

Semin Oncol. 2005 Aug;32(4 Suppl 6):S4-8. Review.

PMID:
16143161
25.

Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study.

Greer BE, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson D, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ.

Gynecol Oncol. 2005 Oct;99(1):71-9.

PMID:
16039699
26.

Treatment goals in ovarian cancer.

Ozols RF.

Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:3-11. Review.

27.

NICE guidelines for ovarian cancer: recommendations versus standard care.

Ozols RF.

Cancer Invest. 2004;22(5):815-7. No abstract available.

PMID:
15581063
28.

Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer.

Ozols RF.

Cancer Invest. 2004;22 Suppl 2:11-20. Review.

PMID:
15573741
29.

Counterpoint: Intraperitoneal chemotherapy: an investigational treatment in ovarian cancer.

Ozols RF.

J Natl Compr Canc Netw. 2004 Nov;2(6):555-60. Review.

PMID:
19780299
30.

Ovarian cancer clinical practice guidelines.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Chen LM, Copeland L, Fiorica J, Fowler J, Gaffney DK, Gershenson D, Greer BE, Grendys EC Jr, Johnston C, Lele S, Matulonis UA, Molpus KL, Ozols RF, Sabbatini P, Santoso JT, Soper J, Teng N; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2004 Nov;2(6):526-47. No abstract available.

PMID:
19780297
31.

Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.

Ozols RF.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S60-73. Review.

PMID:
19780247
32.

Symptoms of ovarian cancer--where to set the bar?

Daly MB, Ozols RF.

JAMA. 2004 Jun 9;291(22):2755-6. No abstract available.

PMID:
15187058
33.

Focus on epithelial ovarian cancer.

Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC.

Cancer Cell. 2004 Jan;5(1):19-24. No abstract available.

34.
35.

Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies.

Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, Hamilton TC, Lynch HT, Godwin AK, Xu XX.

Cancer. 2003 Dec 15;98(12):2607-23.

36.
37.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group.

J Clin Oncol. 2003 Sep 1;21(17):3194-200. Epub 2003 Jul 14.

PMID:
12860964
38.

Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit.

Ozols RF.

J Clin Oncol. 2003 Jul 1;21(13):2451-3. No abstract available.

PMID:
12829660
39.

Specific keynote: chemoprevention of ovarian cancer: the journey begins.

Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast RC Jr, Brewer MA.

Gynecol Oncol. 2003 Jan;88(1 Pt 2):S59-66; discussion S67-70. Review. No abstract available.

PMID:
12586088
40.

ICON3 and chemotherapy for ovarian cancer.

Ozols RF, Markman M, Thigpen JT.

Lancet. 2002 Dec 21-28;360(9350):2086-7; author reply 2088. No abstract available.

PMID:
12504453
41.
42.

Update on the management of ovarian cancer.

Ozols RF.

Cancer J. 2002 May-Jun;8 Suppl 1:S22-30. Review.

PMID:
12075699
43.

Recurrent ovarian cancer: evidence-based treatment.

Ozols RF.

J Clin Oncol. 2002 Mar 1;20(5):1161-3. No abstract available.

PMID:
11870155
44.

Future directions in the treatment of ovarian cancer.

Ozols RF.

Semin Oncol. 2002 Feb;29(1 Suppl 1):32-42. Review.

PMID:
11840418
45.

The current role of gemcitabine in ovarian cancer.

Ozols RF.

Semin Oncol. 2001 Apr;28(2 Suppl 7):18-24. Review.

PMID:
11372048
46.

Optimum chemotherapy for ovarian cancer.

Ozols RF.

Int J Gynecol Cancer. 2000 Jan;10(S1):33-37.

PMID:
11240730
47.

HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.

Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF.

Semin Oncol. 2000 Dec;27(6 Suppl 11):53-63; discussion 92-100. Review.

PMID:
11236029
48.

Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.

Schilder RJ, Gallo JM, Millenson MM, Bookman MA, Weiner LM, Rogatko A, Rogers B, Padavic-Shallers K, Boente M, Rosenblum N, Adams AL, Ciccotto S, Ozols RF.

J Clin Oncol. 2001 Feb 15;19(4):1183-94.

PMID:
11181685
49.

[Epithelial ovarian cancer (advanced stage): consensus conference (1998)].

Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Lück HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Tropé C, Tuxen MK, Vergote I, Vermorken JB, Willemse PH.

Gynecol Obstet Fertil. 2000 Jul-Aug;28(7-8):576-83. Review. French. No abstract available.

PMID:
10996969
50.

Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty.

Ozols RF.

Semin Oncol. 2000 Jun;27(3 Suppl 7):47-9. Review. No abstract available.

PMID:
10952127

Supplemental Content

Loading ...
Support Center